FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie

The FDA has approved AbbVie Inc's ABBV Qulipta (atogepant) to prevent episodic migraines in adults.
Qulipta is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist specifically developed for the preventive treatment of migraine.
Qulipta will be available from early October in three strengths – 10 mg, 30 mg, and 60 mg.
The approval is supported by data from a clinical program in nearly 2,000 patients who experienced 4 to 14 migraine days per month.
All Qulipta dose groups demonstrated statistically significant reductions in mean monthly migraine days compared to placebo.
Patients treated with 60 mg of Qulipta across 12 weeks experienced a 4.2-day reduction from a baseline of 7.8.
Related content: Benzinga's Full FDA Calendar.
Price Action: ABBV stock traded 0.49% higher at $107.87 during the premarket session on the last check Wednesday.

Momentum56.47

Growth40.31

Quality52.44

Value13.40

Short

Medium

Long